Study #2025-1463
A phase 1, open-label study of the absorption, metabolism, and excretion of (14C)-DSP-5336 following a single oral dose in patients with refractory or relapsed acute leukemia, myelodysplastic syndrome, multiple myeloma, or myeloproliferative neoplasms
MD Anderson Study Status
Enrolling
Treatment Agent
DSP-5336, [14C]-DSP-5336
Description
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Hematologic Malignancies
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?